A recent clinical study with 859 adults (456 patients with NAFLD and 403 controls without NAFLD) identifies that circulating prolactin levels and hepatic Prlr gene expression levels are lower in NAFLD patients than those of healthy controls (in both sexes). This evidence concerns the gene PRL and metabolic dysfunction-associated steatotic liver disease.